[
1. WHO. Chronic obstructive pulmonary disease (COPD). Available at https://www.who.int/news-room/factsheets/detail/chronic-obstructive-pulmonary-disease-(copd) Published June 21, 2021. Accessed: July 24, 2021.
]Search in Google Scholar
[
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2021 Report. Available https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed: July 26, 2021.
]Search in Google Scholar
[
3. Lazic Z, Stankovic I, Milenkovic B, Zvezdin B, Hromis S, Jankovic S, et al. Characteristics of COPD Phenotypes in Serbia. Int J Chron Obstruct Pulmon Dis. 2021;16:643-54.10.2147/COPD.S300693798116233758501
]Search in Google Scholar
[
4. Nagorni-Obradovic LM, Vukovic DS. The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim Care Respir Med. 2014;24:14008.10.1038/npjpcrm.2014.8437330024921714
]Search in Google Scholar
[
5. Vukoja M, Kopitovic I, Lazic, Z, Milenkovic B, Stankovic I, Zvezdin B et al. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. Int J Chron Obstruct Pulmon Dis. 2019;14:1993-2002.10.2147/COPD.S214690673054231564847
]Search in Google Scholar
[
6. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez- Padilla R, Postma D, et al; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693-718.10.1164/rccm.200811-1757ST20802169
]Search in Google Scholar
[
7. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study BMC Family Practice. 2015;16:173.10.1186/s12875-015-0387-6
]Search in Google Scholar
[
8. Matte DL, Pizzichini MM, Hoepers AT, Diaz AP, Karloh M, Dias M, et al. Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. Respir Med. 2016;117:154-61.10.1016/j.rmed.2016.06.00627492526
]Search in Google Scholar
[
9. von Haehling S, Anker SD. Cachexia as major underestimated unmet medical need: facts and numbers. Int J Cardiol. 2012;161(3):121-3.10.1016/j.ijcard.2012.09.21323084543
]Search in Google Scholar
[
10. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147(5):1151-6.10.1164/ajrccm/147.5.11518484624
]Search in Google Scholar
[
11. Blakemore A, Dickens C, Guthrie E, Bower P, Kontopantelis E, Afzal C, et al. Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:501-12.10.2147/COPD.S58136403510824876770
]Search in Google Scholar
[
12. Sundh J, Ekström M. Persistent disabling breathlessness in chronic obstructive pulmonary disease. Int J COPD. 2016;11(1):2805-12.10.2147/COPD.S119992510847827877034
]Search in Google Scholar
[
13. Regvat J, Žmitek A, Vegnuti M, Košnik M, Šuškovič S. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res. 2011;39(3):1028-38.10.1177/14732300110390033821819737
]Search in Google Scholar
[
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.10.1136/jnnp.23.1.5649533114399272
]Search in Google Scholar
[
15. Trajković G, Starčević V, Latas M, Leštarević M, Ille T, Bukumirić Z, et al. Reliability of the Hamilton Rating Scale for Depression: A meta-analysis over a period of 49 years. Psychiatry Research, 2011;189(1): 1-9.10.1016/j.psychres.2010.12.00721276619
]Search in Google Scholar
[
16. 16. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionna ire: A New Measure. Psychopharmacology Bulletin 1993;29:321-6.10.1037/t49981-000
]Search in Google Scholar
[
17. Contoli M, Solidoro P, Di Marco F, Scichilone N, Corsico A, Braido F, et al. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. Int J Chron Obstruct Pulmon Dis. 2016;11:30 43-50.10.2147/COPD.S122433514741227980401
]Search in Google Scholar
[
18. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res. 2005;39(2):145-50.10.1016/j.jpsychires.2004.06.00515589562
]Search in Google Scholar
[
19. Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, et al. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry. 2012;200(2):130-6.10.1192/bjp.bp.110.09122322194183
]Search in Google Scholar
[
20. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. Respir Med. 2017;129:117-23.10.1016/j.rmed.2017.06.00728732818
]Search in Google Scholar
[
21. Fan VS, Giardino ND, Blough DK, Kaplan RM, Ramsey SD; Nett Research Group. Costs of pulmonary reha bilitation and predictors of adherence in the National Emphysema Treatment Trial. COPD. 2008;5(2):105-16.10.1080/1541255080194119018415809
]Search in Google Scholar
